Education

2000, Ph.D., Virology, University College London

1998, M.D., Epidemiology, Peking Medical University

1990, M.S., Medical Microbiology and Immunology, National Institutes for Food and Drug Controls (NIFDC)

1987, B.S., Medicine, Qingdao Medical College

Academic Experience

2022-present, Leading Scientist, Changping Laboratory

2022-present, Director, Institute of Medical Biology, Chinese Academy of Medical Sciences

2018-2022,     Chief Expert of vaccine evaluation, NIFDC

2010-2018,     Deputy Director, NIFDC

2000-2010,     Senior Research Fellow, NIFDC

Overview of Academic Research

Dr. Yunchun Wang’s laboratory is mainly focused on the research of epidemiology, molecular biology of human viruses and quality control research of the related products for the prevention and control. Recently, we concentrated on the research of the major emerging infectious diseases, and employed the pseudotyped virus based platform to study the biological and immunological characteristics of SARS-CoV-2, influenza, rabies and other viruses, and developed the key evaluation approaches for the related prophylactic and therapeutic products, which provide technical support for the research and development of broad-spectrum vaccines and therapeutic antibodies.

Major Honor and Awards

Beijing Science & Technology Progress Award, first class, 2021, Led by Youchun Wang

National Science & Technology Progress Award, second class, 2017, Led by Youchun Wang

The 18th Wu Jieping-Paul Janssen Medical Pharmaceutical Award, 2017, Led by Youchun Wang

Beijing Science & Technology Progress Award, first class, 2013, Led by Youchun Wang

New Century Talents Project, 2006

Special allowance from the State Council government, 2004

Representative Research Achievements 

1.  Li, Q., J. Wu, J. Nie, L. Zhang, H. Hao, S. Liu, C. Zhao, Q. Zhang, H. Liu, L. Nie, H. Qin, M. Wang, Q. Lu, X. Li, Q. Sun, J. Liu, L. Zhang, X. Li, W. Huang*, and Y. Wang*. 2020. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity, Cell, 182: 1284-94 e9.

2.  Li, Q., J. Nie, J. Wu, L. Zhang, R. Ding, H. Wang, Y. Zhang, T. Li, S. Liu, M. Zhang, C. Zhao, H. Liu, L. Nie, H. Qin, M. Wang, Q. Lu, X. Li, J. Liu, H. Liang, Y. Shi, Y. Shen, L. Xie, L. Zhang, X. Qu*, W. Xu*, W. Huang*, and Y. Wang*. 2021. SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape, Cell, 184: 2362-71 e9.

3.  Cao, Y.*, J. Wang, F. Jian, T. Xiao, W. Song, A. Yisimayi, W. Huang, Q. Li, P. Wang, R. An, J. Wang, Y. Wang, X. Niu, S. Yang, H. Liang, H. Sun, T. Li, Y. Yu, Q. Cui, S. Liu, X. Yang, S. Du, Z. Zhang, X. Hao, F. Shao, R. Jin, X. Wang*, J. Xiao*, Y. Wang*, and X. S. Xie*. 2022. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies, Nature, 602: 657-63.

4.  Cao, Y.*, Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., Yu, Y., Wang, P., Zhang, Z., Liu, P., An, R., Hao, X., Wang, Y., Wang, J., Feng, R.,  Sun, H.,  Zhao, L., Zhang, W., Zhao,D., Zheng, J., Yu, L., Li, C., Zhang, N.,  Wang, R., Niu, X., Yang, S., Song, X., Chai, Y., Hu, Y., Shi, Y., Zheng, L., Li, Z., Gu, Q., Shao, F., Huang, W., Jin, R., Shen Z.*, Wang, Y.*, Wang, X.*, Xiao, J.*, and Xie, X.S.*. 2022. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection, Nature, 608, 593–602.

5.  Cao, Y.*, F. Jian, J. Wang, Y. Yu, W. Song, A. Yisimayi, J. Wang, R. An, X. Chen, N. Zhang, Y. Wang, P. Wang, L. Zhao, H. Sun, L. Yu, S. Yang, X. Niu, T. Xiao, Q. Gu, F. Shao, X. Hao, Y. Xu, R. Jin, Z. Shen, Y. Wang*, and X. S. Xie*. 2022. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution, Nature, https://doi.org/10.1038/s41586-022-05644-7.

6.  Lv, Z., Y. Q. Deng, Q. Ye, L. Cao, C. Y. Sun, C. Fan, W. Huang, S. Sun, Y. Sun, L. Zhu, Q. Chen, N. Wang, J. Nie, Z. Cui, D. Zhu, N. Shaw, X. F. Li, Q. Li, L. Xie*, Y. Wang*, Z. Rao*, C. F. Qin*, and X. Wang*. 2020. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody, Science, 369: 1505-09.

7.  Nie, J., Q. Li, J. Wu, C. Zhao, H. Hao, H. Liu, L. Zhang, L. Nie, H. Qin, M. Wang, Q. Lu, X. Li, Q. Sun, J. Liu, C. Fan, W. Huang*, M. Xu*, and Y. Wang*. 2020. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay, Nat Protoc, 15: 3699-715.

8.  Yu, Y., M. Wang, X. Zhang, S. Li, Q. Lu, H. Zeng, H. Hou, H. Li, M. Zhang, F. Jiang, J. Wu, R. Ding, Z. Zhou, M. Liu, W. Si, T. Zhu, H. Li, J. Ma, Y. Gu, G. She, X. Li, Y. Zhang, K. Peng, W. Huang*, W. Liu*, and Y. Wang*. 2021. Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients, Signal Transduct Target Ther, 6: 346.

9.  Li, Q., L. Zhang, Z. Liang, N. Wang, S. Liu, T. Li, Y. Yu, Q. Cui, X. Wu, J. Nie, J. Wu, Z. Cui, Q. Lu, X. Wang*, W. Huang*, and Y. Wang*. 2022. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses, Signal Transduct Target Ther, 7: 256.

10.  Zhang, M., Y. An, X. Wu, M. Cai, X. Zhang, C. Yang, J. Tong, Z. Cui, X. Li, W. Huang*, C. Zhao*, and Y. Wang*. 2022. Retrospective immunogenicity analysis of seasonal flu H3N2 vaccines recommended in the past ten years using immunized animal sera, EBioMedicine, 86: 104350.